ClinicalTrials.gg
CompletedNCT01077713Updated Oct 8, 2015Results posted

A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer

A Phase 2 interventional study of bevacizumab [Avastin] and cisplatin in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 26 sites in Italy. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2015-10-08.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
62nd of 149
86 · median 56
Started
2010
with 8 others
Phase 2
95 of 150
6 open now
Registered
73rd of 150
by date
Lead sponsor
10 of 150
Hoffmann-La Roche

Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 62nd largest by enrollment of the 149 interventional ones that give a count, is one of 9 that started in 2010, is one of 95 in phase 2, and was the 73rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This 2 arm study will evaluate the efficacy and safety of Avastin + gemcitabine, and Avastin + gemcitabine + attenuated doses of cisplatin, as first line treatment in elderly patients with non-squamous non-small cell lung cancer. Patients will be randomised to receive either Avastin 7.5mg/kg iv on day 1 + gemcitabine 1200mg/m2 on days 1-8 of each 3 week cycle, or Avastin 7.5mg/kg iv on day 1 + cisplatin 60mg/m2 on day 1 + gemcitabine 1000mg/m2 on days 1-8 of each 3 week cycle. After 6 cycles of combination therapy, all patients will continue to receive Avastin monotherapy. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=70 years of age;
  • inoperable, locally advanced, non-squamous non-small cell lung cancer;
  • >=1 ;
  • performance status 0-1.

Exclusion criteria

Exclusion Criteria:

  • /adjuvant chemotherapy within 6 months prior to enrollment;
  • radical radiotherapy with curative intent within 28 days prior to enrollment;
  • history of >=grade 2 hemoptysis in 3 months prior to enrollment;
  • evidence of ;
  • current or recent (within 10 days of first dose of Avastin)use of aspirin (>325 mg/day)or full dose anticoagulants or thrombolytic agents for therapeutic purposes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: gemcitabine

  • Experimental
    2

    Drug: bevacizumab [Avastin] · Drug: cisplatin · Drug: gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Alive and Without Progressive Disease at Month 6

    Disease progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (v 1.1). Disease progression was defined at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), progression of existing non-target lesions, or presence of new lesions.

    Time frame: Month 6

Secondary outcomes

  1. Percentage of Participants With Disease Progression or Death

    Disease progression was assessed according to RECIST criteria v1.1. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.

    Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)

  2. Progression Free Survival (PFS)

    PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Disease progression was assessed according to RECIST criteria v 1.1. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.

    Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)

  3. Percentage of Participants Alive at 12 Months After Randomization

    Time frame: 1 year

  4. Percentage of Participants Who Died

    Time frame: From randomization to death or end of the study (up to 53 months)

  5. Overall Survival (OS)

    OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.

    Time frame: From randomization to death or end of the study (up to 53 months)

  6. Percentage of Participants by Best Overall Response

    Best overall response was defined as the best response recorded from the start of the treatment until disease progression/recurrence, assessed according to RECIST criteria v 1.1. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to less than (\<) 10 millimeter (mm) in short axis; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions; Progressive Disease (PD): at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)

  7. Percentage of Participants With an Objective Response

    Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.

    Time frame: Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6

  8. Percentage of Participants With Disease Control

    Disease control was defined as having CR/PR/SD as per RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.

    Time frame: Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6

  9. Duration of Response (DoR)

    DoR was defined for participants who had achieved an objective response (CR/PR) (whichever status was recorded first) as the time period from first documentation of a response to the date of first occurrence of investigator documented disease progression or death. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as increase by at least 20% in the sum of the longest diameters of each target lesion, taking as a reference the smallest sum of the longest diameters or appearance of one or more new lesions. DoR was estimated using Kaplan Meier method.

    Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)

07

Results

Posted Oct 8, 2015

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Started4442
Completed86
Not completed3636
Withdrew: Withdrawal by subject12
Withdrew: Progressive disease (pd)01
Withdrew: Death2829
Withdrew: Lost to follow-up11
Withdrew: Adverse event21
Withdrew: Other42

Outcome measures

PrimaryPercentage of Participants Alive and Without Progressive Disease at Month 6

Disease progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (v 1.1). Disease progression was defined at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), progression of existing non-target lesions, or presence of new lesions.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants Alive and Without Progressive Disease at Month 6
percentage of participantsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Percentage of Participants Alive and Without Progressive Disease at Month 625.6 (12.5 to 38.6)30.0 (15.8 to 44.2)
SecondaryPercentage of Participants With Disease Progression or Death

Disease progression was assessed according to RECIST criteria v1.1. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.

Time frame:
Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death
percentage of participantsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Percentage of Participants With Disease Progression or Death86.090.0
SecondaryProgression Free Survival (PFS)

PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Disease progression was assessed according to RECIST criteria v 1.1. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.

Time frame:
Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Progression Free Survival (PFS)4.33 (2.20 to 5.97)6.82 (4.49 to 8.52)
SecondaryPercentage of Participants Alive at 12 Months After Randomization
Time frame:
1 year
Reported as:
Number · percentage of participants
Percentage of Participants Alive at 12 Months After Randomization
percentage of participantsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Percentage of Participants Alive at 12 Months After Randomization37.2 (22.8 to 51.7)47.5 (32.0 to 63.0)
SecondaryPercentage of Participants Who Died
Time frame:
From randomization to death or end of the study (up to 53 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Percentage of Participants Who Died69.872.5
SecondaryOverall Survival (OS)

OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.

Time frame:
From randomization to death or end of the study (up to 53 months)
Reported as:
Median · months
Overall Survival (OS)
monthsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Overall Survival (OS)5.66 (3.38 to 13.0)12.0 (9.93 to 19.6)
SecondaryPercentage of Participants by Best Overall Response

Best overall response was defined as the best response recorded from the start of the treatment until disease progression/recurrence, assessed according to RECIST criteria v 1.1. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to less than (\<) 10 millimeter (mm) in short axis; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions; Progressive Disease (PD): at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)
Reported as:
Number · percentage of participants
Percentage of Participants by Best Overall Response
percentage of participantsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
CR0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
PR14.0 (3.6 to 24.3)35.0 (20.2 to 49.8)
SD39.5 (24.9 to 54.1)37.5 (22.5 to 52.5)
PD16.3 (5.2 to 27.3)12.5 (2.2 to 22.7)
Not Assessable30.2 (16.5 to 44.0)15.0 (3.9 to 26.1)
SecondaryPercentage of Participants With an Objective Response

Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.

Time frame:
Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response
percentage of participantsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Cycle 311.6 (2.05 to 21.2)27.5 (13.7 to 41.3)
Cycle 69.3 (0.62 to 18.0)15.0 (3.93 to 26.1)
Month 64.7 (0.00 to 10.9)10.0 (0.70 to 19.3)
SecondaryPercentage of Participants With Disease Control

Disease control was defined as having CR/PR/SD as per RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.

Time frame:
Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control
percentage of participantsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Cycle 353.5 (38.6 to 68.4)67.5 (53.0 to 82.0)
Cycle 627.9 (14.5 to 41.3)37.5 (22.5 to 52.5)
Month 625.6 (12.5 to 38.6)30.0 (15.8 to 44.2)
SecondaryDuration of Response (DoR)

DoR was defined for participants who had achieved an objective response (CR/PR) (whichever status was recorded first) as the time period from first documentation of a response to the date of first occurrence of investigator documented disease progression or death. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as increase by at least 20% in the sum of the longest diameters of each target lesion, taking as a reference the smallest sum of the longest diameters or appearance of one or more new lesions. DoR was estimated using Kaplan Meier method.

Time frame:
Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)
Reported as:
Median · months
Duration of Response (DoR)
monthsBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
Duration of Response (DoR)5.23 (3.93 to NA)5.97 (2.20 to 9.08)

Adverse events

Collected over From baseline to 28 days after last dose of any study drug (up to 54 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Gemcitabine—17/43 (39.5%)38/43 (88.4%)
Bevacizumab + Gemcitabine + Cisplatin—10/40 (25%)37/40 (92.5%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
EmbolismVascular disorders1/432/40
General physical health deteriorationGeneral disorders2/430/40
DyspnoeaRespiratory, thoracic and mediastinal disorders2/430/40
HaemoptysisRespiratory, thoracic and mediastinal disorders2/430/40
Respiratory failureRespiratory, thoracic and mediastinal disorders2/430/40
Atrial fibrillationCardiac disorders0/431/40
Myocardial infarctionCardiac disorders0/431/40
NauseaGastrointestinal disorders0/431/40
PneumoniaInfections and infestations0/431/40
FallInjury, poisoning and procedural complications0/431/40
Most frequent other events
Showing 10 of 35
Most frequent other events
EventBevacizumab + GemcitabineBevacizumab + Gemcitabine + Cisplatin
NeutropeniaBlood and lymphatic system disorders12/4323/40
NauseaGastrointestinal disorders8/4317/40
ThrombocytopeniaBlood and lymphatic system disorders5/4316/40
FatigueGeneral disorders8/4315/40
AnaemiaBlood and lymphatic system disorders5/4312/40
LeukopeniaBlood and lymphatic system disorders0/4311/40
HypertensionVascular disorders11/439/40
AstheniaGeneral disorders9/4310/40
ConstipationGastrointestinal disorders3/438/40
PyrexiaGeneral disorders8/438/40

Baseline characteristics

All participants randomized set (RND) included all participants who provided informed consent and who were randomized to study medication.

Age, Continuous
Age, Continuous(years)Bevacizumab + GemcitabineBevacizumab + Gemcitabine + CisplatinTotal
Mean74.2 ± 3.273.8 ± 3.574.0 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + GemcitabineBevacizumab + Gemcitabine + CisplatinTotal
Female161228
Male283058
08

Study locations

26 sites
  • Rionero in Vulture, Basilicata 85028, Italy
  • Catanzaro, Calabria 88100, Italy
  • Avellino, Campania 83100, Italy
  • Napoli, Campania 80131, Italy
  • Bologna, Emilia-Romagna 40139, Italy
  • Aviano, Friuli-Venezia Giulia 33081, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Roma, Lazio 00128, Italy
  • Roma, Lazio 00152, Italy
  • Roma, Lazio 00189, Italy
  • Viterbo, Lazio 01100, Italy
  • Genova, Liguria 16149, Italy
  • Bergamo, Lombardia 24128, Italy
  • Milano, Lombardia 20142, Italy
  • Monza, Lombardia 20052, Italy
  • Rho, Lombardia 20017, Italy
  • Sondalo, Lombardia 23039, Italy
  • Sondrio, Lombardia 23100, Italy
  • Ancona, Marche 60121, Italy
  • Pesaro, Marche 61122, Italy
  • Novara, Piemonte 28100, Italy
  • Catania, Sicilia 95100, Italy
  • Lido Di Camaiore, Toscana 55043, Italy
  • Perugia, Umbria 06156, Italy
  • Mirano, Veneto 30035, Italy
  • Padova, Veneto 35128, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2010
First posted
Mar 1, 2010
Start
Feb 2010
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Oct 8, 2015
Last update
Oct 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01077713
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 1, 2010
Start date
Feb 2010
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Oct 8, 2015
Last update
Oct 8, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Gemcitabine

Start the discussion